RELAPSING - REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING - REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING - REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gut bacteria swap explored as MS treatment in early trial
Disease control TerminatedThis early-phase study tested whether a fecal transplant from a healthy donor could be safe and affect the immune system in people with relapsing-remitting multiple sclerosis. Only 5 participants were enrolled before the study was stopped. The goal was to see if changing gut bact…
Matched conditions: RELAPSING - REMITTING MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Jeffrey Gelfand • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental MS drug tested in kids, but study halted early
Disease control TerminatedThis study tested the drug alemtuzumab in children aged 10 to 18 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. The goal was to see if the drug could reduce new brain lesions and improve quality of life. However, the tria…
Matched conditions: RELAPSING - REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
MS drug trial halted after failing to lower nerve damage
Disease control TerminatedThis study tested an oral drug called SAR443820 in 174 adults with multiple sclerosis (MS) to see if it could lower a marker of nerve damage in the blood. The trial was stopped early because the drug did not meet its main goal of reducing that marker. Participants were followed f…
Matched conditions: RELAPSING - REMITTING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Blood test may predict dangerous MS rebound after stopping popular drug
Knowledge-focused TerminatedThis small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting M…
Matched conditions: RELAPSING - REMITTING MULTIPLE SCLEROSIS
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
What sets off MS Flare-Ups? scientists investigate stress and hormones
Knowledge-focused TerminatedThis study looked at how stress, hormonal cycles, illness, and missed medications might affect when symptoms appear or get worse in women with relapsing-remitting multiple sclerosis (RR-MS). Researchers planned to track 80 women over time, recording daily symptom changes. The stu…
Matched conditions: RELAPSING - REMITTING MULTIPLE SCLEROSIS
Sponsor: University of Louisville • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
MRI scans aim to predict tysabri success in MS patients
Knowledge-focused TerminatedThis study looked at whether special MRI scans can detect early brain changes in people with multiple sclerosis who are starting treatment with Tysabri. Researchers planned to follow 70 patients for two years, comparing MRI images before and after treatment. The goal was to find …
Matched conditions: RELAPSING - REMITTING MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC